Annual Operating Profit
-$38.07 M
+$280.00 K+0.73%
31 December 2023
Summary:
Galectin Therapeutics annual operaing income is currently -$38.07 million, with the most recent change of +$280.00 thousand (+0.73%) on 31 December 2023. During the last 3 years, it has fallen by -$14.63 million (-62.40%). GALT annual operating profit is now -1644.74% below its all-time high of -$2.18 million, reached on 31 December 2001.GALT Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
-$9.07 M
+$2.23 M+19.71%
30 September 2024
Summary:
Galectin Therapeutics quarterly operating income is currently -$9.07 million, with the most recent change of +$2.23 million (+19.71%) on 30 September 2024. Over the past year, it has increased by +$100.00 thousand (+1.09%). GALT quarterly operating profit is now -1443.67% below its all-time high of -$587.30 thousand, reached on 30 June 2001.GALT Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$39.57 M
+$100.00 K+0.25%
30 September 2024
Summary:
Galectin Therapeutics TTM operating income is currently -$39.57 million, with the most recent change of +$100.00 thousand (+0.25%) on 30 September 2024. Over the past year, it has dropped by -$422.00 thousand (-1.08%). GALT TTM operating profit is now -6636.93% below its all-time high of -$587.30 thousand, reached on 30 June 2001.GALT TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.7% | +1.1% | -1.1% |
| 3 y3 years | -62.4% | -10.0% | -29.4% |
| 5 y5 years | -179.9% | -216.7% | -252.2% |
GALT Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -62.4% | +0.7% | -22.1% | +19.7% | -31.1% | +0.3% |
| 5 y | 5 years | -183.3% | +0.7% | -216.7% | +19.7% | -252.2% | +0.3% |
| alltime | all time | -1644.7% | +0.7% | -1443.7% | +19.7% | -6636.9% | +0.3% |
Galectin Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.07 M(-19.7%) | -$39.57 M(-0.3%) |
| June 2024 | - | -$11.29 M(+17.0%) | -$39.67 M(+6.1%) |
| Mar 2024 | - | -$9.65 M(+0.9%) | -$37.38 M(-1.8%) |
| Dec 2023 | -$38.07 M(-0.7%) | -$9.56 M(+4.3%) | -$38.07 M(-2.7%) |
| Sept 2023 | - | -$9.17 M(+1.8%) | -$39.14 M(+2.7%) |
| June 2023 | - | -$9.00 M(-12.9%) | -$38.10 M(-1.7%) |
| Mar 2023 | - | -$10.34 M(-2.7%) | -$38.76 M(+1.1%) |
| Dec 2022 | -$38.35 M(+27.1%) | -$10.63 M(+30.9%) | -$38.35 M(+9.1%) |
| Sept 2022 | - | -$8.12 M(-15.9%) | -$35.14 M(-0.3%) |
| June 2022 | - | -$9.66 M(-2.7%) | -$35.27 M(+4.3%) |
| Mar 2022 | - | -$9.94 M(+33.8%) | -$33.80 M(+12.0%) |
| Dec 2021 | -$30.18 M(+28.7%) | -$7.42 M(-9.9%) | -$30.18 M(-1.3%) |
| Sept 2021 | - | -$8.24 M(+0.6%) | -$30.59 M(+8.2%) |
| June 2021 | - | -$8.19 M(+29.7%) | -$28.27 M(+8.0%) |
| Mar 2021 | - | -$6.32 M(-19.3%) | -$26.18 M(+11.7%) |
| Dec 2020 | -$23.44 M(+74.5%) | -$7.83 M(+32.2%) | -$23.44 M(+12.7%) |
| Sept 2020 | - | -$5.93 M(-2.9%) | -$20.80 M(+17.3%) |
| June 2020 | - | -$6.10 M(+70.3%) | -$17.74 M(+21.0%) |
| Mar 2020 | - | -$3.58 M(-30.9%) | -$14.65 M(+9.1%) |
| Dec 2019 | -$13.44 M(-1.2%) | -$5.19 M(+81.2%) | -$13.44 M(+19.6%) |
| Sept 2019 | - | -$2.86 M(-5.2%) | -$11.23 M(+1.7%) |
| June 2019 | - | -$3.02 M(+27.6%) | -$11.05 M(-6.3%) |
| Mar 2019 | - | -$2.37 M(-20.7%) | -$11.79 M(-13.3%) |
| Dec 2018 | -$13.60 M(-16.3%) | -$2.98 M(+11.4%) | -$13.60 M(+4.7%) |
| Sept 2018 | - | -$2.68 M(-28.7%) | -$12.99 M(-11.8%) |
| June 2018 | - | -$3.76 M(-10.0%) | -$14.72 M(-4.9%) |
| Mar 2018 | - | -$4.18 M(+76.1%) | -$15.48 M(-4.7%) |
| Dec 2017 | -$16.25 M(-24.4%) | -$2.37 M(-46.2%) | -$16.25 M(-12.1%) |
| Sept 2017 | - | -$4.41 M(-2.2%) | -$18.47 M(-0.7%) |
| June 2017 | - | -$4.51 M(-8.7%) | -$18.60 M(-5.2%) |
| Mar 2017 | - | -$4.95 M(+7.5%) | -$19.61 M(-8.7%) |
| Dec 2016 | -$21.48 M(+7.0%) | -$4.60 M(+1.4%) | -$21.48 M(-0.4%) |
| Sept 2016 | - | -$4.54 M(-18.0%) | -$21.57 M(-5.9%) |
| June 2016 | - | -$5.53 M(-18.8%) | -$22.93 M(+4.0%) |
| Mar 2016 | - | -$6.81 M(+45.5%) | -$22.05 M(+9.8%) |
| Dec 2015 | -$20.08 M(+30.1%) | -$4.68 M(-20.6%) | -$20.08 M(+5.0%) |
| Sept 2015 | - | -$5.90 M(+26.7%) | -$19.13 M(+14.5%) |
| June 2015 | - | -$4.66 M(-3.8%) | -$16.71 M(+8.3%) |
| Mar 2015 | - | -$4.84 M(+29.6%) | -$15.43 M(-0.0%) |
| Dec 2014 | -$15.43 M(+27.5%) | -$3.73 M(+7.4%) | -$15.43 M(+6.4%) |
| Sept 2014 | - | -$3.48 M(+3.0%) | -$14.50 M(-0.5%) |
| June 2014 | - | -$3.38 M(-30.3%) | -$14.57 M(+6.0%) |
| Mar 2014 | - | -$4.84 M(+72.8%) | -$13.74 M(+13.5%) |
| Dec 2013 | -$12.10 M(+22.3%) | -$2.80 M(-20.9%) | -$12.10 M(+3.6%) |
| Sept 2013 | - | -$3.54 M(+39.2%) | -$11.68 M(+5.9%) |
| June 2013 | - | -$2.55 M(-20.6%) | -$11.03 M(-1.1%) |
| Mar 2013 | - | -$3.21 M(+34.7%) | -$11.15 M(+12.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$9.90 M(-4.9%) | -$2.38 M(-17.7%) | -$9.90 M(-9.1%) |
| Sept 2012 | - | -$2.90 M(+8.5%) | -$10.89 M(+8.6%) |
| June 2012 | - | -$2.67 M(+36.6%) | -$10.03 M(-3.1%) |
| Mar 2012 | - | -$1.95 M(-42.1%) | -$10.35 M(-0.6%) |
| Dec 2011 | -$10.41 M(+113.2%) | -$3.37 M(+65.9%) | -$10.41 M(+25.0%) |
| Sept 2011 | - | -$2.03 M(-32.0%) | -$8.33 M(+10.9%) |
| June 2011 | - | -$2.99 M(+48.6%) | -$7.50 M(+28.0%) |
| Mar 2011 | - | -$2.01 M(+56.2%) | -$5.86 M(+20.1%) |
| Dec 2010 | -$4.88 M(-19.9%) | -$1.29 M(+6.4%) | -$4.88 M(+3.7%) |
| Sept 2010 | - | -$1.21 M(-10.2%) | -$4.71 M(-0.8%) |
| June 2010 | - | -$1.35 M(+30.8%) | -$4.75 M(-11.9%) |
| Mar 2010 | - | -$1.03 M(-7.6%) | -$5.39 M(-11.5%) |
| Dec 2009 | -$6.09 M(+14.4%) | -$1.12 M(-10.6%) | -$6.09 M(+0.3%) |
| Sept 2009 | - | -$1.25 M(-37.2%) | -$6.08 M(+5.4%) |
| June 2009 | - | -$1.99 M(+14.9%) | -$5.77 M(+2.1%) |
| Mar 2009 | - | -$1.73 M(+57.5%) | -$5.65 M(+6.0%) |
| Dec 2008 | -$5.33 M(-17.5%) | -$1.10 M(+17.3%) | -$5.33 M(-5.2%) |
| Sept 2008 | - | -$939.00 K(-49.9%) | -$5.62 M(-7.1%) |
| June 2008 | - | -$1.87 M(+32.7%) | -$6.04 M(+1.7%) |
| Mar 2008 | - | -$1.41 M(+1.5%) | -$5.94 M(-7.9%) |
| Dec 2007 | -$6.46 M(-8.4%) | -$1.39 M(+1.7%) | -$6.46 M(+1.5%) |
| Sept 2007 | - | -$1.37 M(-22.8%) | -$6.36 M(-8.1%) |
| June 2007 | - | -$1.77 M(-7.9%) | -$6.92 M(-4.5%) |
| Mar 2007 | - | -$1.92 M(+48.5%) | -$7.25 M(+2.8%) |
| Dec 2006 | -$7.05 M(+5.9%) | -$1.30 M(-32.8%) | -$7.05 M(-6.3%) |
| Sept 2006 | - | -$1.93 M(-8.1%) | -$7.52 M(+3.1%) |
| June 2006 | - | -$2.10 M(+21.8%) | -$7.30 M(+5.4%) |
| Mar 2006 | - | -$1.72 M(-2.5%) | -$6.93 M(+4.1%) |
| Dec 2005 | -$6.66 M(-8.9%) | -$1.77 M(+3.8%) | -$6.66 M(-6.0%) |
| Sept 2005 | - | -$1.71 M(-1.3%) | -$7.08 M(-1.3%) |
| June 2005 | - | -$1.73 M(+18.9%) | -$7.17 M(+4.2%) |
| Mar 2005 | - | -$1.45 M(-33.8%) | -$6.88 M(-5.8%) |
| Dec 2004 | -$7.30 M(+47.9%) | -$2.19 M(+22.0%) | -$7.30 M(+8.8%) |
| Sept 2004 | - | -$1.80 M(+25.2%) | -$6.71 M(+6.3%) |
| June 2004 | - | -$1.44 M(-23.3%) | -$6.31 M(+7.8%) |
| Mar 2004 | - | -$1.87 M(+16.9%) | -$5.86 M(+18.6%) |
| Dec 2003 | -$4.94 M(+50.2%) | -$1.60 M(+14.5%) | -$4.94 M(+11.6%) |
| Sept 2003 | - | -$1.40 M(+42.6%) | -$4.42 M(+20.8%) |
| June 2003 | - | -$981.90 K(+3.0%) | -$3.66 M(+4.0%) |
| Mar 2003 | - | -$953.10 K(-12.5%) | -$3.52 M(+7.2%) |
| Dec 2002 | -$3.29 M(+50.6%) | -$1.09 M(+70.5%) | -$3.29 M(+12.2%) |
| Sept 2002 | - | -$639.00 K(-24.1%) | -$2.93 M(+0.1%) |
| June 2002 | - | -$841.50 K(+17.3%) | -$2.93 M(+9.5%) |
| Mar 2002 | - | -$717.20 K(-2.2%) | -$2.67 M(+36.7%) |
| Dec 2001 | -$2.18 M | -$733.10 K(+15.3%) | -$1.96 M(+59.9%) |
| Sept 2001 | - | -$635.80 K(+8.3%) | -$1.22 M(+108.3%) |
| June 2001 | - | -$587.30 K | -$587.30 K |
FAQ
- What is Galectin Therapeutics annual operaing income?
- What is the all time high annual operating profit for Galectin Therapeutics?
- What is Galectin Therapeutics annual operating profit year-on-year change?
- What is Galectin Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly operating profit year-on-year change?
- What is Galectin Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Galectin Therapeutics?
- What is Galectin Therapeutics TTM operating profit year-on-year change?
What is Galectin Therapeutics annual operaing income?
The current annual operating profit of GALT is -$38.07 M
What is the all time high annual operating profit for Galectin Therapeutics?
Galectin Therapeutics all-time high annual operaing income is -$2.18 M
What is Galectin Therapeutics annual operating profit year-on-year change?
Over the past year, GALT annual operaing income has changed by +$280.00 K (+0.73%)
What is Galectin Therapeutics quarterly operating income?
The current quarterly operating profit of GALT is -$9.07 M
What is the all time high quarterly operating profit for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly operating income is -$587.30 K
What is Galectin Therapeutics quarterly operating profit year-on-year change?
Over the past year, GALT quarterly operating income has changed by +$100.00 K (+1.09%)
What is Galectin Therapeutics TTM operating income?
The current TTM operating profit of GALT is -$39.57 M
What is the all time high TTM operating profit for Galectin Therapeutics?
Galectin Therapeutics all-time high TTM operating income is -$587.30 K
What is Galectin Therapeutics TTM operating profit year-on-year change?
Over the past year, GALT TTM operating income has changed by -$422.00 K (-1.08%)